ACM
BCYC icon

ADAR1 Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

ADAR1 Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-54,100
Closed -$978K – 270
2023
Q4 		$978K Buy
+54,100
New +$895K 0.35% 46

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

ADAR1 Capital Management's BCYC Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Bicycle Therapeutics (BCYC) stake by 29% in Q2 2026, selling an estimated $94.7K and leaving 50,638 shares worth $215K. The position accounts for 0.01% of the portfolio, ranked #248.

ADAR1 Capital Management first reported a position in BCYC in Q4 2023 and has held it in 4 quarters since. The position peaked at $1.35M in Q4 2023. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • ADAR1 Capital Management held 50,638 shares of Bicycle Therapeutics worth $215K as of Q2 2026.
  • ADAR1 Capital Management sold 20,660 Bicycle Therapeutics shares in Q2 2026, an estimated $94.7K.
  • Bicycle Therapeutics made up 0.01% of ADAR1 Capital Management's portfolio in Q2 2026, its #248 holding.
  • ADAR1 Capital Management first reported a position in Bicycle Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • ADAR1 Capital Management's Bicycle Therapeutics position peaked at $1.35M in Q4 2023.
  • 103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.